Soterix Medical Inc.

Soterix Medical is the global leader in non-invasive neuromodulation and integrated brain monitoring technology. The company designs, manufactures, and markets advanced research and clinical-grade systems for transcranial electrical stimulation (tDCS, tES, HD-tES), transcranial magnetic stimulation (TMS, MEGA-TMS), transcranial focused ultrasound stimulation (tFUS), and related modalities. Research platforms include 1x1 tDCS/tES systems, high-definition HD-tES platforms, temporal interference stimulation (TI), taVNS (transcutaneous auricular vagus nerve stimulation), galvanic vestibular stimulation, and fully integrated multimodal solutions combining stimulation with EEG, fMRI, PET, and fNIRS. Clinical systems target depression (tDCS-LTE), pain conditions (PainX tDCS and TENS), and major depressive disorder (SPRY TMS). The company also offers neurotargeting software (HD-Explore, HD-Targets, tDCS-Explore), mobile EEG systems, and animal pre-clinical stimulation systems. Soterix holds FDA 510(k) clearances for multiple products including Depression tDCS-LTE, SPRY TMS, IontoDC, MEGA-IOM intraoperative neuromonitoring, and Neural Navigator TMS neuronavigation. CE Mark approvals exist for 1x1 tDCS depression and PainX pain treatment. The company serves academic research centers, clinical institutions, and specialized neurology and psychiatry practices worldwide. Manufacturing and quality standards reflect commitment to precision, usability, and regulatory compliance across research and clinical applications.